If you have hypertrophic cardiomyopathy (HCM) and are experiencing symptoms such as shortness of breath, chest pain, ...
The Global Ventricular Tachycardia Market is estimated to be valued at USD 15.52 Bn in 2025 and is expected to reach USD 22.28 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 5.3% from ...
Woman's World on MSN
Is your BP pill making you tired? This MD shares what to avoid
"The main side effect is them not working! Not everyone responds to every drug." The common blood pressure drug you may want ...
SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...
Patients who start their blood pressure treatment with ARB drugs continue with the same medicine to a greater extent than patients who start out with other drugs. Choosing the right drug from the ...
The FDA approved etripamil (Cardamyst) nasal spray for at-home treatment of paroxysmal supraventricular tachycardia (PSVT), maker Milestone Pharmaceuticals announced. The rapid-acting L-type calcium ...
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has given Milestone Pharmaceuticals its first FDA approval in its 22-year history. The ...
The US Food and Drug Administration has approved etripamil nasal spray (Cardamyst) for adults with acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT), drugmaker Milestone ...
(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) is awaiting a pivotal U.S. FDA decision this month on the company's lead drug candidate, CARDAMYST nasal spray, for the acute treatment of paroxysmal ...
Introduction: Tumor necrosis factor-α (TNF-α) is considered a potential therapeutic strategy for cancers, as it exacerbates calcium influx through voltage-gated calcium channels (VGCCs), thereby ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback